<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HEE37F786086B4DAD9AE84176EAD44E5D" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6963 IH: Accelerated Approval Integrity Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6963</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220307">March 7, 2022</action-date><action-desc><sponsor name-id="P000034">Mr. Pallone</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for postapproval studies for drugs approved using accelerated approval, and for other purposes.</official-title></form><legis-body id="H19CB3F13B5224EC3B90702751615B7C9" style="OLC"><section id="H1C54B6A92A2E4AC2AD57CBB12563BF55" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Accelerated Approval Integrity Act of 2022</short-title></quote>. </text></section><section id="H81635CB4C87D42E8B69487E42126404B"><enum>2.</enum><header>Postapproval studies required for accelerated approval drugs</header><subsection id="H57B9DB5C932544C4A8474718DA7B2015"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356">21 U.S.C. 356(c)</external-xref>) is amended—</text><paragraph id="HF523574E9FC44EE596708A7D502528DB"><enum>(1)</enum><text>in paragraph (2)—</text><subparagraph id="H8E559B2A76A64027B7B5613C3CB33049"><enum>(A)</enum><text>in the matter preceding subparagraph (A), by striking <quote>may be subject to 1 or both of </quote> and inserting <quote>shall be subject to</quote>;</text></subparagraph><subparagraph id="H764FBC2255824FC8B5EE10354643502F"><enum>(B)</enum><text display-inline="yes-display-inline">by amending subparagraph (A) to read as follows: </text><quoted-block style="OLC" id="HBD908CD976254998AC13063C9EC1E99A" display-inline="no-display-inline"><subparagraph id="H0CD41EA3F88B49B7801CFF2C569723FA"><enum>(A)</enum><header>Postapproval studies</header><clause id="H239354438B89468CB2F99E851B5866BC"><enum>(i)</enum><header>In general</header><text>The sponsor of a product approved under accelerated approval shall—</text><subclause id="H3F981A77F82E456DB7DB5C0A98058C7A"><enum>(I)</enum><text display-inline="yes-display-inline">conduct appropriate, adequate, and well-controlled postapproval studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit; and</text></subclause><subclause id="H62C4A8EF7BA84B2DB8396CE740484903"><enum>(II)</enum><text>submit reports on such studies in accordance with section 506B.</text></subclause></clause><clause id="H25D9010FE7AA450FAF4B76962639C850"><enum>(ii)</enum><header>Agreement</header><text display-inline="yes-display-inline">The Secretary and the sponsor shall enter into an agreement regarding the required conduct of such studies prior to the Secretary approving a product under accelerated approval. Such agreement may include requirements regarding enrollment targets, study protocol, and milestones, including the target date of study completion. </text></clause><clause id="H0DF55085710C49A7A99348414306A8BF"><enum>(iii)</enum><header>Studies begun before approval</header><text display-inline="yes-display-inline">The Secretary may—</text><subclause id="H748900CD22B94BADBCBEB76FAAEFD675"><enum>(I)</enum><text>require such studies to be underway prior to approval; and</text></subclause><subclause id="HA2ADD35430F6499ABE2AF45885F10562"><enum>(II)</enum><text>refuse to approve a product under accelerated approval until such studies are underway.</text></subclause></clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="H81F0312BAADF47B5B6B158C484E183D9"><enum>(C)</enum><text>in subparagraph (B), by striking <quote><header-in-text level="subparagraph" style="OLC"><enum-in-header>(B) </enum-in-header></header-in-text>That the sponsor</quote> and inserting the following: </text><quoted-block style="OLC" id="H8D8A6EB1E7CB4EE4A4637ADBC6883C04" display-inline="no-display-inline"><subparagraph id="H2F6A1A9A4E9A4E898809F618CF2145F1"><enum>(B)</enum><header>Promotional materials</header><text display-inline="yes-display-inline">The sponsor of a product approved under accelerated approval shall</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H21E067038CD342A7A428374927823B47"><enum>(2)</enum><text>by striking paragraph (3) and inserting the following: </text><quoted-block style="OLC" id="HAE21B8F3FD0E4FFB9E3BD87106274F53" display-inline="no-display-inline"><paragraph id="H6A7AD901741A46A2B64EF276E97CB1A1"><enum>(3)</enum><header>Expedited withdrawal of approval</header><subparagraph id="H7298C6E08D58441ABBFA0B9DF8746353"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary may withdraw approval of a product approved under accelerated approval using expedited procedures described in subparagraph (B), if—</text><clause id="HAA9871070A674BCFB0B77A8BD3238F7E"><enum>(i)</enum><text display-inline="yes-display-inline">the sponsor fails to conduct any required postapproval study of the product with due diligence;</text></clause><clause id="H963B4544659746AE98ADEBA0637BFE38"><enum>(ii)</enum><text display-inline="yes-display-inline">the sponsor fails to achieve agreed upon enrollment targets, milestones, or timely study completion;</text></clause><clause id="H5ACCF09EA4BB4C2EB0F2C92B46A1F4D0"><enum>(iii)</enum><text display-inline="yes-display-inline">the sponsor fails to submit reports in accordance with section 506B;</text></clause><clause id="H8DEC0CFEDF194B028E3AC841682381DC"><enum>(iv)</enum><text display-inline="yes-display-inline">a study required to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit of the product fails to verify and describe such effect or benefit;</text></clause><clause id="H8632D0FFB3824691952820CE581D5477"><enum>(v)</enum><text display-inline="yes-display-inline">other evidence demonstrates that the product is not shown to be safe or effective under the conditions of use; or</text></clause><clause id="H4A9722BA3C2846BFAECFF49C226BAAF3"><enum>(vi)</enum><text display-inline="yes-display-inline">the sponsor disseminates false or misleading promotional materials with respect to the product.</text></clause></subparagraph><subparagraph id="H7E359C0491724513A06E65970C9BA1B9"><enum>(B)</enum><header>Expedited procedures described</header><text display-inline="yes-display-inline"><italic></italic>Expedited procedures described in this subparagraph—</text><clause id="H7694DBF7493E4AD38C3BF4FAB22E573F"><enum>(i)</enum><text>shall consist of—</text><subclause id="H14C6C5BAA4AC4C22A0C78E66949B8561"><enum>(I)</enum><text display-inline="yes-display-inline">providing the sponsor due notice and an opportunity for written appeal to the Commissioner of Food and Drugs; and</text></subclause><subclause id="H5A7F3DCF2FE54DF48E94A331C1C2E255"><enum>(II)</enum><text>an opportunity for public comment on the notice proposing to withdraw approval; and</text></subclause></clause><clause id="H1A0ABF7957D34DACBA05CEDC1F89918E"><enum>(ii)</enum><text>may include, at the Secretary’s discretion, convening and consulting an advisory committee.</text></clause></subparagraph><subparagraph id="H56BEA0EA88644832B69C7B8246C1FD5E"><enum>(C)</enum><header>Automatic expiration</header><text display-inline="yes-display-inline">The approval of a product approved under accelerated approval after the date of enactment of the <short-title>Accelerated Approval Integrity Act of 2022</short-title> shall automatically expire 1 year after any target date of study completion included in an agreement described in clause (ii) of paragraph (2)(A), and in no case later than 5 years after the date on which the product is approved, unless—</text><clause id="H9122C48AB5E649D9AEB95C8085F51007"><enum>(i)</enum><text display-inline="yes-display-inline">a study required to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical benefit of the product has verified that predicted effect; or</text></clause><clause id="H461860BBF99B4672B06FB726B6F627D5"><enum>(ii)</enum><text display-inline="yes-display-inline">the Secretary has determined that adequate progress has been made on completion of postapproval studies required under paragraph (2)(A).</text></clause></subparagraph></paragraph><paragraph id="HB3933911FA4C4A3D9A56BF2216FA26AD"><enum>(4)</enum><header>Labeling</header><subparagraph id="H6B6508CF9B2448F7AC3476DF063DBBE9"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subparagraph (B), the label for a product approved under accelerated approval shall include—</text><clause id="HE8C69922BDC449ED972295DDBB907357"><enum>(i)</enum><text>a statement indicating that the product was approved under accelerated approval; </text></clause><clause id="H355A00F8074F45DCAFC9C46883D88815"><enum>(ii)</enum><text>a statement indicating that continued approval of the product is subject to postmarketing studies to verify clinical benefit;</text></clause><clause id="H25ADE973A38049ADA50D1C079E7E10A3"><enum>(iii)</enum><text display-inline="yes-display-inline">identification of the clinical endpoint that is under study and any known limitations of that surrogate or intermediate endpoint in determining clinical benefit; </text></clause><clause id="HD1DC81E052CC4889B906178684A432CB"><enum>(iv)</enum><text>a succinct description of the product and any uncertainty about anticipated clinical benefit and a discussion of available evidence with respect to such clinical benefit; and</text></clause><clause id="H37BA90C75DA24B5690D9333758BA0998"><enum>(v)</enum><text>any other information required by the Secretary in the order approving the product.</text></clause></subparagraph><subparagraph id="H7479B6A8BDB344FA83E5EBE69EBEA0DF"><enum>(B)</enum><header>Applicability</header><text display-inline="yes-display-inline">The labeling requirements of subparagraph (A) shall apply only to products approved under accelerated approval for which the predicted effect on irreversible morbidity or mortality or other clinical benefit has not been verified.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H9D60FBDD65694D208153C517ACB97AEF"><enum>(b)</enum><header>Reports of postmarketing studies</header><text>Section 506B(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356b">21 U.S.C. 356b(a)</external-xref>) is amended—</text><paragraph id="HB3C7482E886E462E95FFD0F4347581BF"><enum>(1)</enum><text>by redesignating paragraph (2) as paragraph (3); and</text></paragraph><paragraph id="H481617E1506D4B7FB3952402E3ED84A9"><enum>(2)</enum><text>by inserting after paragraph (1) the following: </text><quoted-block style="OLC" id="H7BC9E1A98AC645C6815A3783C88F95E7" display-inline="no-display-inline"><paragraph id="HF292294CEE41469C92279B71D9DD02BE"><enum>(2)</enum><header>Accelerated approval</header><text display-inline="yes-display-inline">Notwithstanding paragraph (1), a sponsor of a drug approved under accelerated approval shall submit to the Secretary a report of the progress of any study required under section 506(c), including progress toward any agreed upon enrollment targets, milestones, and other information as required by the Secretary, not later than 90 days after the approval of such drug and not less frequently than every 90 days thereafter, until the study is completed or terminated. </text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H86AFCA9615204CEE9D71B28F209C8BBE"><enum>(c)</enum><header>Enforcement</header><text display-inline="yes-display-inline">Section 301 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>) is amended by inserting after paragraph (eee) the following: </text><quoted-block style="OLC" id="H443B98B1E934401588AD9E8AA092E70C" display-inline="no-display-inline"><subsection id="HF7936A8969344A51B3AB11E58ADE7EFB"><enum>(fff)</enum><text display-inline="yes-display-inline">The failure of a sponsor of a product approved under accelerated approval pursuant to section 506(c)—</text><paragraph id="H0FB867DB1AD44CAABEBB93F7C946F3D8"><enum>(1)</enum><text>to conduct with due diligence any postapproval study required under section 506(c) with respect to such product; or</text></paragraph><paragraph id="H305C3DCF719245EEB5AB0B2A42C45B42"><enum>(2)</enum><text>to submit timely reports with respect to such product in accordance with section 506B(a)(2).</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

